Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro. by Shipman, C, Croucher, P

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myelom... by Shipman, C, Croucher, P

Osteoprotegerin and the development of myeloma bone disease by Croucher, P, Shipman, C, Vanderkerken, K

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss? by Shipman, C, Lippitt, J, Croucher, P

Bisphosphonates and in vivo models of multiple myeloma - Reply by Shipman, C, Croucher, P, Vanderkerken, K

Tumor-host cell interactions in the bone disease of myeloma. by Fowler, J, Edwards, C, Croucher, P

Growth Factors by Hulley, P, Russell, G, Croucher, P

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. by Locklin, R, Croucher, P, Russell, R, Edwards, C

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro by Mueller, G, Vanderkerken, K, Russell, R, Croucher, P

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis by Locklin, R, Russell, R, Croucher, P, Edwards, C

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma by Mueller, G, Vanderkerken, K, Russell, R, Croucher, P

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors. by Locklin, R, Croucher, P, Russell, R, Shipman, C

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. by Holen, I, Croucher, P, Hamdy, F, Eaton, C

Clinical disorders of bone resorption. by Russell, G, Mueller, G, Shipman, C, Croucher, P

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand. by Shipman, C, Holen, I, Lippitt, J, Edwards, T, Croucher, P

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. by Croucher, P, Shipman, C, Van Camp, B, Vanderkerken, K

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression. by Holen, I, Wells, J, Croucher, P, Hamdy, F, Eaton, C

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. by Shipman, C, Rogers, M, Apperley, J, Russell, R, Croucher, P

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. by Jagdev, S, Coleman, R, Shipman, C, Rostami-H, A, Croucher, P

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. by Shipman, C, Holen, I, Lippitt, J, Vandenberghe, E, Croucher, P